Technical Due Diligence of Private Equity Acquisition
Evaluation of Diagnostic Company's Clinical Chemistry Spin-Out
The client, a leading private equity firm, was evaluating acquisition of a target company that was being spun out of a large healthcare company. The client had assembled a due diligence team and required additional technical expertise to evaluate the target company's products, pipeline, and technologies.
The short time-frame we had to conduct our assessment required us to focus on the technical feasibility of the company's product development plans, and its portfolio (test menu).
Reviewed company documents provided
Attended an on-site visit, including presentations and tours of product development activities
Prepared and asked questions to the company, at an on-site visit and subsequently by teleconference calls
Developed product development and product performance benchmarks based on our proprietary data and through interviews with external experts
Prepared a briefing deck for our client summarizing our findings
Participated in a Q&A with the client to address questions related to our findings
The client proceeded with the acquisition, which successfully closed at ~$4Bn